Last reviewed · How we verify
Semaglutide 1.0 mg
At a glance
| Generic name | Semaglutide 1.0 mg |
|---|---|
| Also known as | ozempic |
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of CS060380 Tablets in Patients With MASH and Obesity (PHASE2)
- A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight (PHASE3)
- A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease (PHASE2)
- A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (PHASE3)
- Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (PHASE3)
- Effects of Semaglutide in HIV-Associated Lipohypertrophy (PHASE2)
- A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease (PHASE3)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semaglutide 1.0 mg CI brief — competitive landscape report
- Semaglutide 1.0 mg updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI